Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017.
Smith TO., Mansfield M., Hawker GA., Hunter DJ., March LM., Boers M., Shea BJ., Christensen R., Guillemin F., Terwee CB., Williamson PR., Roos EM., Loeser RF., Schnitzer TJ., Kloppenburg M., Neogi T., Ladel CH., Kalsi G., Kaiser U., Buttel TW., Ashford AE., Mobasheri A., Arden NK., Tennant A., Hochberg MC., de Wit M., Tugwell P., Conaghan PG.
OBJECTIVE: To assess the uptake of the OMERACT-OARSI (Outcome Measures in Rheumatology- Osteoarthritis Research Society International) core outcome set (COS) domains in hip and/or knee osteoarthritis (OA) trials. METHODS: There were 382 trials of hip and/or knee OA identified from the ClinicalTrial.gov registry from 1997 to 2017. Frequency of COS adoption was assessed by year and per 5-yearly phases. RESULTS: COS adoption decreased from 61% between 1997 and 2001 to 38% between 2012 and 2016. Pain (95%) and physical function (86%) were most consistently adopted. Patient's global assessment (48%) was the principal missing domain. CONCLUSION: Limited adoption of the COS domains indicates that further consideration to improve uptake is required.